Aug 3, 7:05 AM ET
TG Therapeutics reported second quarter 2026 total revenue of $240.3 million, up from $141.1 million a year earlier, and raised its full-year 2026 total global revenue target to approximately $950 million. Net income fell to $7.8 million from $28.2 million as research and development and selling, general and administrative expenses rose sharply, so higher sales did not translate into higher profit.
- Q2 2026 total revenue was $240.3 million, versus $141.1 million in Q2 2025; BRIUMVI U.S. net product revenue was $227.7 million.
- Q2 2026 net income was $7.8 million ($0.05 diluted per share), versus $28.2 million ($0.17 diluted per share) in Q2 2025.
- Q2 2026 R&D expense was $95.3 million and SG&A expense was $82.1 million, versus $31.8 million and $55.6 million a year earlier.
- Full-year 2026 targets were raised: total global revenue to approximately $950 million and BRIUMVI U.S. net product revenue to approximately $890 to $905 million.
Read the filing on SEC.gov ↗
May 6, 7:25 AM ET
TG Therapeutics reported first quarter 2026 total revenue of $204.9 million, up from $120.9 million a year earlier, and net income of $19.8 million, up from $5.1 million. The company raised its full-year 2026 total global revenue target to approximately $925 million and its BRIUMVI U.S. net product revenue target to $885-900 million, from $825-850 million.
- Total revenue was $204.9 million versus $120.9 million for Q1 2025; BRIUMVI U.S. net product revenue was $194.8 million, about 63% higher year over year.
- Net income was $19.8 million, with diluted EPS of $0.12 versus $0.03 in Q1 2025.
- SG&A expense rose to $88.2 million from $50.3 million, and R&D expense was $48.4 million versus $46.4 million.
- Second quarter 2026 BRIUMVI U.S. net product revenue target is approximately $220 million.
Read the filing on SEC.gov ↗
Mar 20, 4:33 PM ET
TG Therapeutics entered a first amendment to its financing agreement on March 18, 2026, establishing a $750 million term loan maturing March 18, 2031, fully borrowed at closing, with part of the proceeds used to repay the existing Initial Term Loans in full. The filing also sets up an uncommitted additional facility of up to $250 million, and the loan is secured by substantially all assets of the company and its guarantor subsidiaries.
- $750 million 2026 Term Loan borrowed in full on March 18, 2026, with proceeds partly used to repay Initial Term Loans
- Loan matures March 18, 2031; quarterly amortization of $37.5 million begins with the quarter ending March 31, 2030
- Pricing grid starts at 4.75% for SOFR borrowings and 3.75% for base rate borrowings, with a 25 basis point step-down tied to leverage
- Uncommitted additional facility of up to $250 million; Blue Owl Capital Corporation is administrative agent
Read the filing on SEC.gov ↗
Feb 26, 7:08 AM ET
TG Therapeutics reported fourth-quarter and full-year 2025 results, with total revenue of $192.6 million for the quarter and $616.3 million for the year, driven by BRIUMVI sales. Fourth-quarter net income was $23.0 million, slightly below the prior-year quarter, while full-year net income of $447.2 million includes a non-recurring income tax benefit of approximately $339.8 million. The company set a 2026 target of approximately $875-$900 million in total global revenue.
- Q4 2025 total revenue was $192.6 million, versus $108.2 million in Q4 2024; full-year 2025 total revenue was $616.3 million, versus $329.0 million in 2024.
- Q4 2025 net income was $23.0 million, versus $23.3 million in Q4 2024; full-year 2025 net income of $447.2 million includes a tax benefit of approximately $339.8 million.
- 2026 targets: total global revenue of approximately $875-$900 million and BRIUMVI U.S. net product revenue of approximately $825-$850 million.
- Cash, cash equivalents and investment securities were $199.5 million as of December 31, 2025; a new share repurchase program of up to $100 million was announced.
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.